Document Detail


A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3.
MedLine Citation:
PMID:  23183282     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Zesiewicz et al.(1) reported that varenicline improved ataxia in patients with spinocerebellar ataxia type 3 (SCA3) with excellent tolerance. We used open-label varenicline in a similar dosing schedule from 2 weeks to greater than 6 months in 7 patients with ataxia (3 SCA3, 1 multiple system atrophy with cerebellar features, 3 ataxia of unknown etiology).
Authors:
Barbara S Connolly; L K Prashanth; Binit B Shah; Connie Marras; Anthony E Lang
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurology     Volume:  79     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2218     Citation Subset:  AIM; IM    
Affiliation:
Toronto.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  7T MRI of spinal cord injury.
Next Document:  Early thalamic lesions in patients with sleep-potentiated epileptiform activity.